Verismo doses first subject in Phase I trial of SynKIR-310
Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310. The subject was dosed …
Post
-
-
2024 was a record year for obesity trials and 2025 is already poised to take over
There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of …
-
JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic
In moves that continue to strengthen its affiliation with the healthcare industry, NVIDIA has added three new companies to its …
-
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial
Canadian biotech ProMIS Neurosciences has initiated a Phase Ib trial of its lead therapeutic candidate, PMN310, designed to treat Alzheimer’s …
-
Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or without maintenance in subjects …
-
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial
Canadian biotech ProMIS Neurosciences has initiated a Phase Ib trial of its lead therapeutic candidate, PMN310, designed to treat Alzheimer’s …
-
Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or without maintenance in subjects …
-
Respite from rising trial costs is a distant dream in 2025
There is a significant discourse in the literature when estimating clinical trial costs due to the lack of transparency throughout …
-
HMNC completes subject randomisation in Phase IIb MDD treatment trial
HMNC Brain Health (HMNC) has completed the subject randomisation in its placebo-controlled Phase IIb OLIVE trial of a vasopressin V1b …
-
Arcturus Therapeutics launches Phase I Avian Influenza trials in US
California vaccine company Arcturus Therapeutics has announced the launch of a Phase I trial of ARCT-2304, a self-amplifying mRNA (sa-mRNA) …
-
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy
Danish biotechnology company IO Biotech has finished enrolling subjects in a Phase II trial of its lead therapeutic cancer vaccine …
-
IMG Biosciences enacts massive lay-offs after Phase I trial failure
California-based biotech, IGM Biosciences, has put a halt to the development of two of its autoimmune disease therapies, imvotamab and …
-
Alentis Therapeutics reports positive results from organ fibrosis treatment trials
Swiss pharmaceutical company Alentis Therapeutics has reported positive topline outcomes from two clinical trials of its monoclonal antibody, lixudebart (ALE.F02), …
-
Sanofi reports positive results from trial of multiple myeloma drug candidate
French pharmaceutical company Sanofi has reported results from its Phase III IRAKLIA trial, which evaluated Sarclisa (isatuximab) as a potential …
-
South Korean study shows high prevalence of smoking among HIV patients
Among patients with human immunodeficiency virus (HIV) infection, smoking is associated with a higher risk of mortality and HIV-related complications. …
